Obesity: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• GLP-1 168
• PPAR 0
• FTO 0
• AMPK 3
• GIP 20
• SGLT2 5
• STAT3 0
• SIRT1 0
• PI3K 0
• NRF2 0
• AKT 0
• mTOR 2
• NLRP3 3
• MAPK 0
• TP53 0
• TNF 0
• IL-6 1
• TLR4 0
• BDNF 2
• DPP-4 1
• JNK 0
• APOE 0
• ERK 0
• IL-17 1
• PTEN 0
• STING 0
• ACE2 0
• HIF-1 0
• PCSK9 0
• VEGF 0
• IL-1 0
• JAK 0
• PNPLA3 2
• YAP 0
• HMGB1 0
• CTNNB1 0
• HER2 0
• MMP-9 0
• PD-L1 0
• PINK1 0
• TFEB 0
• TREM2 0
• CCR5 0
• FGFR 0
• GPX4 0
• IGF1R 0
• IL-23 0
• METTL3 0
• PD-1 0
• STK11 0
• AR 0
• BCL-2 0
• CFTR 0
• COX-2 0
• HDAC 0
• EGFR 0
• HSP90 0
• MEK 0
• MYC 0
• PKM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Small Bowel Diversion

  NCT06374368· University of Ostrava· Updated 6 Nov 2026

  “Halted for safety concerns after jejuno-colic diversion: frequent and serious late complications, incl. hepatic fibrosis, lean body mass loss and surgical reversal of the anastomosis.”Registry text, quoted unchanged. Source

• Terminated

  Probiotics and Insulin Resistance in Obese Asthmatics

  NCT05949255· University of Alabama at Birmingham· Updated 5 Nov 2026

  “Lost coordinator and statistician before no cost extension study could be completed.”Registry text, quoted unchanged. Source

• Suspended

  The Impact of Continuous Glucose Monitoring on Glucose Variability and Weight Loss in Individuals With Prediabetes and Obesity

  NCT07423065· University of Primorska· Updated 4 Nov 2026

  “The study has been temporarily suspended pending approval from the Slovenian Agency for Medicinal Products and Medical Devices (JAZMP). The need for this additional regulatory approval was identified following communication with JAZMP.”Registry text, quoted unchanged. Source

• Terminated

  Physical Exercise Prehabilitation Program in mEtabolic suRgery

  NCT06889207· Flevoziekenhuis· Updated 30 Oct 2026

  “Higher dropout rate (38% versus the 10% on which the original sample size was based). Interim analysis revealed that the effect on the primary outcome measure was already highly statistically significant.”Registry text, quoted unchanged. Source

• Suspended

  Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

  NCT01105858· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Updated 29 Oct 2026

  “Recruitment temporarily paused.”Registry text, quoted unchanged. Source

• Withdrawn

  GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

  NCT07677865· West China Hospital· Updated 16 Oct 2026

  “poor accrual and funding issues”Registry text, quoted unchanged. Source

• Terminated

  A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

  NCT07553299· Verdiva Bio Dev Limited· Updated 13 Oct 2026

  “The Study Sponsor made a business decision not to continue the study. The decision was not based on safety findings.”Registry text, quoted unchanged. Source

• Withdrawn

  An Open-Label Study of Diazoxide Choline in Patients With Genetic Obesities

  NCT05532020· Soleno Therapeutics, Inc.· Updated 13 Oct 2026

  “Company Decision”Registry text, quoted unchanged. Source

• Terminated

  Weight Management Program for Obese Preschool Children

  NCT07126210· Peking University· Updated 16 Sept 2026

  “Study terminated prematurely due to poor accrual. The actual number of eligible children recruited from kindergartens was far lower than expected, making the study unfeasible.”Registry text, quoted unchanged. Source

• Suspended

  A Food Security Intervention for the Prevention of Cancer in Low-income Families

  NCT07039630· Roswell Park Cancer Institute· Updated 15 Sept 2026

  “behavioral intervention is being prepared”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  NCT07575399· Amgen· Source

• A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity

  NCT07874633· Pfizer· Source

• Optimal Digital Weight Loss Treatment for Rural Individuals

  NCT06105957· University of South Carolina· Source

• A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti

  NCT03892265· Washington University School of Medicine· Source

• A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)

  NCT07794774· Pfizer· Source

• A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes

  NCT07922330· AstraZeneca· Source

• Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults

  NCT07388537· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

• A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)

  NCT07881757· Pfizer· Source

• Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors

  NCT05687604· Northwestern University· Source

• AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  NCT07533175· Novo Nordisk A/S· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 20
• Organoids 10
• Mendelian Randomization Analysis 179
• CRISPR-Cas Systems 7
• Gene Expression Profiling 142
• Sequence Analysis, RNA 10
• Whole Genome Sequencing 4
• Exome Sequencing 19
• Proteomics 125
• Metabolomics 190
• Mass Spectrometry 28
• Flow Cytometry 16
• Immunohistochemistry 41
• Xenograft Model Antitumor Assays 15
• Positron-Emission Tomography 25
• Magnetic Resonance Imaging 254
• Machine Learning 154
• Deep Learning 20
• Cohort Studies 1007
• Genome-Wide Association Study 201

• Transcriptional and phenotypic alterations of regulatory and effector T cells in type 1 diabetes mellitus.

  Mol Biomed, Oct 2026

• Integrative Transcriptomic Analysis of Obesity-Associated Candidate Genes in Pediatric Adipose Tissue.

  J Vis Exp, Oct 2026

• Expression Analysis of microRNAs in Peripheral Blood Mononuclear Cells in Type 2 Diabetes.

  Biomolecules, Oct 2026

• Skeletal Muscle Transcriptomic Responses to a High-Fat, High-Sugar Diet Across Sex and Maturation in Mice.

  Nutrients, Oct 2026

• Human Subcutaneous Adipose Transcriptomes Link Mitochondrial Transcription to Metabolic Heterogeneity in Obesity.

  Genes (Basel), Sept 2026

• Imidacloprid exposure is associated with brown adipose tissue impairment in high-fat diet-fed C57BL/6 mice.

  Food Res Int, Sept 2026

• Transcriptomic analysis of bone marrow adipose tissue reveals enrichment in lipid transport in response to a Western diet.

  Endocrinology, Sept 2026

• Single-cell profiling of pancreatic islets maps subtype-associated molecular alterations in type 2 diabetes.

  Diabetologia, Sept 2026

• Biological Pathways of Strength Preservation During Calorie Restriction-Induced Weight Loss Among Adults Without Obesity.

  Obesity (Silver Spring), Sept 2026

• Co-Administration of Trans-Resveratrol and L-Carnitine with a High-Fat and High-Carbohydrate Diet Modulates Liver Transcriptome in Obesity-Resistant DBA/2J Mice.

  Int J Mol Sci, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.